Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Summary

The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.

Timeline

Start

2006-09

Primary completion

2007-10

Completion

2007-10

Publications

• Results Zakko S, Barton G, Weber E, Dunger-Baldauf C, Ruhl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011 Jun;33(12):1311-21. doi: 10.1111/j.1365-2036.2011.04656.x. Epub 2011 Apr 20.

Drugs

Indications